Search Results

News & Media

News & Media Sharing our impact with the world Advancing science, earning recognition At Rho, we’re proud to see our work making headlines. From groundbreaking research contributions to industry accolades, our team is continually driving progress in clinical development. Here, you’ll find the latest news, awards, and resources to stay

Rho Awarded 2023 Best Places to Work

Rho has once again been chosen as a winner of Triangle Business Journal’s 2023 Best Places to Work Awards. This is the 11th year Rho has been recognized for the Triangle Business Journal’s award “a prestigious award that honors companies for creating policies and a work environment that employees value.”

One of the most rewarding aspects of this recognition is that it is driven by employee surveys, which are then tabulated and ranked by Quantum Workplace. Rho is honored and proud to receive high marks in areas such as team effectiveness, trust with co-workers, manager effectiveness and work engagements from our employees.

Rho Receives 2023 CRO Leadership Award

Rho received Clinical Leader and Life Science Leader’s 2023 CRO Leadership award, marking a long history as an award recipient. Forty-six CROs were evaluated on more that 20 different performance metrics. Respondents evaluated companies with which they have worked on an outsourced project within the past 18 months. This level of qualification ensures that survey responses are based on actual involvement with CROs and clear experiential data.

Rho was recognized for Exceeding Customer Expectations in Compatibility and Quality and received 4 Individual Attribute Awards in Data Quality, Technology for Real Time Access to Data, Therapeutic Expertise and Operational Excellence.

RMAT Designation…What is it and is it Right for Your Therapeutic Product?

As research teams develop more cellular and gene therapy products for the treatment of a wide array of medical conditions, the need for custom nonclinical and clinical programs required to support market approval of products that are based on human cells, tissues, or HCT/P will rise. And for RMAT designated products, the study designs may be substantially different from more traditional IND programs.